Araie Makoto, Kitazawa Yoshiaki, Azuma Ikuo, Shirato Shiroaki, Hamanaka Teruhiko, Tomita Goji, Origasa Hideki
University of Tokyo, Tokyo, Japan.
J Ocul Pharmacol Ther. 2003 Dec;19(6):517-25. doi: 10.1089/108076803322660431.
We investigated the dose-escalation profile of dorzolamide used in combination with other antiglaucoma agents in patients with primary glaucoma and ocular hypertension. In a prospective, open-label study, 78 patients received dorzolamide 0.5% in addition to other topical antiglaucoma agents for > or =4 weeks. The concentration of dorzolamide was then escalated to 1.0% and intraocular pressure (IOP) measured every 4 weeks for 12 weeks. Dose escalation of dorzolamide from 0.5% to 1.0% resulted in a significant reduction in IOP throughout the 12 weeks of treatment at the higher dose. Mean baseline IOP was 19.7 mmHg. At 4, 8, and 12 weeks after dose escalation, mean IOP had decreased to 17.8 (-9.4%), 17.6 (-10.8%), and 17.5 (-10.7%) mmHg. No serious drug-related adverse effects were reported. These results indicate that dose escalation of dorzolamide from 0.5% to 1.0% is effective and well tolerated as adjunctive therapy for patients in whom IOP is insufficiently controlled by combination therapy.
我们研究了多佐胺与其他抗青光眼药物联合用于原发性青光眼和高眼压症患者时的剂量递增情况。在一项前瞻性、开放标签研究中，78例患者在接受其他局部抗青光眼药物治疗≥4周的基础上，加用0.5%的多佐胺。然后将多佐胺浓度增至1.0%，并在12周内每4周测量一次眼压（IOP）。在较高剂量的12周治疗期间，多佐胺从0.5%增至1.0%导致眼压显著降低。平均基线眼压为19.7 mmHg。在剂量递增后的4周、8周和12周，平均眼压分别降至17.8（-9.4%）、17.6（-10.8%）和17.5（-10.7%）mmHg。未报告严重的药物相关不良反应。这些结果表明，对于联合治疗眼压控制不佳患者，多佐胺从0.5%增至1.0%作为辅助治疗是有效且耐受性良好的。
